Jefferies Group’s Rigel Pharmaceuticals RIGL Stock Holding History

Jefferies Group’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-4,500	Closed	-$161K	–	3467
2015 Q1	$161K	Buy	+4,500	New	+$123K	﹤0.01%	1814

Other funds holding RIGL

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tamarack Advisers Carlsbad, California $2.12M AUM 58.09% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Group's RIGL Position: Q4 2019 in Review

Jefferies Group sold out of Rigel Pharmaceuticals (RIGL) in Q4 2019, closing a stake of 1,712 shares — an estimated $32K sold.

Jefferies Group first reported a position in RIGL in Q1 2015 and held it in 5 quarters. The position peaked at $248K in Q3 2018. 136 funds tracked by Wall St. Rank hold RIGL as of Q4 2019.

Jefferies Group reported no remaining Rigel Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
Jefferies Group sold 1,712 Rigel Pharmaceuticals shares in Q4 2019, an estimated $32K.
Jefferies Group first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 5 quarters.
Jefferies Group's Rigel Pharmaceuticals position peaked at $248K in Q3 2018.
136 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q4 2019.

Based on Jefferies Group's 13F filing for Q4 2019, filed 13 Feb 2020.